March 15 - 17, 2014 | Qatar
Featuring: Huda Akil (University of Michigan), Karl Deisseroth (Stanford University)
Join global experts in clinical neuroscience in Doha, Qatar, for a 2.5 day, two-track conference that will feature recent advances in the understanding and treatment of mood disorders, stroke, and traumatic brain injury.
Tuesday, April 8, 2014 | 8:30 AM - 4:30 PM
Speakers: Dan V. Iosifescu (Icahn School of Medicine at Mount Sinai), Daniel C. Javitt (Columbia University and Nathan Kline Institute), John H. Krystal (Yale University), Andrew F. Leuchter (University of California, Los Angeles), Gregory Light (University of California, San Diego), Siva Digavalli (Bristol-Myers Squibb), Eva Redei (Northwestern University), Steven J. Siegel (University of Pennsylvania)
Recent breakthrough insights from clinical studies are illuminating the neurobiology of psychiatric disorders. This symposium explores differences in sensory processing, imaging, and other biomarkers that may translate findings to animal models.
Thursday, April 10, 2014 | 8:30 AM - 4:30 PM
Speakers: Robert Balaban (National Heart, Lung, and Blood Institute, NIH), Robert Bao (Massachusetts General Hospital), Salvatore DiMauro (Columbia University Medical Center), Steven Gross (Weill Cornell Medical College), Costas A. Lyssiotis (Weill Cornell Medical College), Vamsi K. Mootha (Harvard Medical School), Jared Rutter (University of Utah School of Medicine), Hazel H. Szeto (Weill Cornell Medical College), Benjamin P. Tu (UT Southwestern Medical Center)
Damage to mitochondria, which are critical in metabolism, underlies a wide range of human diseases, making them an important therapeutic target. Researchers aim to characterize and cure diseases arising from aberrant mitochondrial metabolism.
Friday, May 9, 2014 | 8:00 AM - 4:00 PM
Speakers: Carmela R. Abraham (Boston University School of Medicine), Eric H. Baehrecke (University of Massachusetts Medical School), Nir Barzilai (Albert Einstein College of Medicine), Jerry R. Colca (Metabolic Solutions Development Company), Brendan D. Manning (Harvard School of Public Health), Beth Stevens (Harvard Medical School), D. Martin Watterson (Northwestern University Feinberg School of Medicine), Haung Yu (Columbia University), Jeffrey W. Kelly (The Scripps Research Institute), Richard I. Morimoto (Northwestern University)
Age is the major risk factor for Alzheimer's disease, and key pathways in aging biology offer targets for novel drugs. Explore recent advances in the science of aging and innovative drug discovery for Alzheimer’s and other neurodegenerative diseases.
Tuesday, September 30, 2014 | 8:00 AM - 5:00 PM
Keynote Speaker: Nobel Laureate Robert J. Lefkowitz (Duke University Medical Center)
Speakers: Bryan Roth (University of North Carolina at Chapel Hill School of Medicine), Terry Kenakin (University of North Carolina at Chapel Hill School of Medicine), Marc G. Caron (Duke University Medical Center), Laura Bohn (The Scripps Research Institute), Michael Ehlers (Pfizer), JoAnn Trejo (University of California-San Diego), Jonathan Violin (Trevena, Inc.)
Hear academic, industry, basic and translational researchers, including Nobel Laureate Robert Lefkowitz (Duke University Medical Center) and discuss the development of functionally selective GPCR-biased ligands for CV and CNS disease drug discovery.
Tuesday, December 10, 2013 | 8:30 AM - 4:30 PM
Speakers: Frank M. LaFerla (University of California, Irvine), Sylvain E. Lesné (University of Minnesota), Bingwei Lu (Stanford University School of Medicine), Lennart Mucke (Gladstone Institute of Neurological Disease), Ralph A. Nixon (Nathan Kline Institute), Franck Polleux (Columbia University), Terrence Town (University of Southern California), Tony Wyss-Coray (Stanford University School of Medicine)
Organizers: Ken Jones (Forest Research Institute), Robert Martone (Covance Biomarker Center of Excellence),
Robert B. Nelson (Lundbeck Research USA), Jennifer Henry (The New York Academy of Sciences)
This symposium explores how efforts to better integrate our understanding of neuritic plaques and neurofibrillary tangles—the two hallmark pathologies of Alzheimer's disease—are leading to a 'truce' between former rivals in the quest for therapies.
November 6 - 7, 2013
Organizers: Alan Cross (AstraZeneca), Sonya Dougal (formerly at The New York Academy of Sciences), Howard Feldman (University of British Columbia), Surya Kolluri (Bank of America), Ian Kremer (Leaders Engaged on Alzheimer's Disease), Tetsuyuki Maruyama (Takeda), Richard C. Mohs (Eli Lilly and Company), Jeffrey S. Nye (Janssen R&D), Ronald C. Petersen (Mayo Clinic), Gregory A. Petsko (Weill Cornell Medical College), Andrea Pfeifer (AC Immune), Thomas Rooney (Sanofi), Darryle D. Schoepp (Merck and Company, Inc.), Diane Stephenson (Critical Path Institute), Rudolph E. Tanzi (Harvard Medical School), John Q. Trojanowski (University of Pennsylvania), Diana L. van de Hoef (The New York Academy of Sciences), George Vradenburg (The Global CEO Initiative on Alzheimer's Disease), Michael Weiner (University of California, San Francisco), Michael Krams (Janssen R&D)
NIA Technical Advisor: Neil Buckholtz (National Institute on Aging/NIH)
This conference will convene leading industry, academic, and government stakeholders to discuss how to prevent and effectively treat Alzheimer's by 2025, by coordinating with governmental efforts to build research resources, reengineer our current drug development and evaluation systems, and identify innovative technologies and financing models. The outcome of this meeting will comprise a research agenda that will delineate the pathways needed to effectively treat and prevent Alzheimer's disease by 2025.
Thursday, October 24, 2013 | 8:30 AM - 7:00 PM
Speakers: Charles H. Adler (Mayo Clinic Arizona / Arizona Parkinson's Disease Consortium), Raymond Bartus (RTBioconsultants, Inc.), Donald E. Frail (AstraZeneca PLC), Reina Fuji, VMD (Genentech Inc.), Kimberley S. Gannon (NeuroPhage Pharmaceuticals, Inc.), Kenneth Marek (Institute for Neurodegenerative Disorders), Mary Maral Mouradian (Rutgers - Robert Wood Johnson Medical School), Adrian Newman-Tancredi (Neurolixis, Inc.), Michael A. Schwarzschild (Massachusetts General Hospital), Eric Siemers (Eli Lilly and Company), Peggy Taylor (Covance Inc.)
Explore emerging basic and translational research that impacts our understanding of Parkinson's Disease and its treatment.
Wednesday, September 18, 2013 | 5:00 PM - 6:45 PM
Moderator: Orla M. Smith (Science Translational Medicine)
Panelists: Amanda Boxtel (Ekso Bionics), Grégoire Courtine (Swiss Federal Institute of Technology, EPFL), Nathan Harding (Ekso Bionics)
Join us for a discussion of cutting-edge technologies that may revolutionize spinal cord injury rehabilitation and treatment. Included in the discussion is a live demonstration of a wearable robot (or exoskeleton) that enables people with lower-extremity paralysis or weakness to stand and walk. We will present perspectives from an innovator, a researcher, and a patient, who will share their insights on how these new technologies benefit the public now and in the future to come.
Edited by Sonia Sequeira
(Memorial Sloan-Kettering Cancer Center, New York, New York)
This Annals volume explores the ways in which meditative practice can affect consciousness, brain structure and function, aging, and clinical outcomes.
Edited by Annals of the New York Academy of Sciences
This Annals volume presents three meeting reports: (1) Probiotics, Prebiotics, and the Host Microbiome: the Science of Translation; (2) Capacity Building in Nutrition Science: Revisiting the Curricula for Medical Professionals; and (3) Circadian Clocks, Brain Function, and Development.
Keynote Speaker: Robert J. Greenberg (Alfred E. Mann Foundation)
This eBriefing explores the translation of neurotechnologies into new treatment options for neurological and psychiatric diseases.
Edited by Annals of the New York Academy of Sciences
This Annals volume presents a collection of papers stemming from two conferences: (1) Evolutionary Dynamics and Information Hierarchies in Biological Systems: Aspen Center for Physics workshop; and (2) Cracking the Neural Code: Third Annual Aspen Brain Forum.
Neuroscientist Richard Restak thinks with the right mental exercises, our brains can be much better. Today he teams with writer Susan Orlean to talk about our brainy potential.
What attracts us to a mate? Is "chemistry" really to blame for love at first sight? Biological anthropologist Helen Fisher explains the science behind our mating preferences.
Can meditation have long-term beneficial effects on the plasticity of our brains? Bon meditation practitioner Alejandro Chaoul and oncologist Lorenzo Cohen evaluate the healing potential of meditation in a discussion from the Rubin Museum of Art's Brainwave Festival.
February 19, 2010
Science journalist and adventure-seeker Jeff Wise talks about his new book Extreme Fear: The Science of Your Mind in Danger.
February 23, 2010
Researchers met to discuss advances in basic and translational research on metabotropic glutamate receptors, which are promising targets in drug discovery for CNS diseases and other illnesses.
October 27, 2009
What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.
Translational Medicine Initiative
The Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.
Learn more at www.nyas.org/TransMed.